You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Advances in

HR-Positive Breast Cancer

The treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer is rapidly evolving. Recent approvals of mechanistic target of rapamycin (mTOR) inhibitors and cyclin dependent kinase (CDK) 4/6 inhibitors have the potential to change the treatment armamentarium for this patient population and ultimately improve outcomes. Clinicians are faced with increasingly complex decision-making and must be educated on the optimal use of these agents in clinical practice.

Supported by an independent educational grant from


CME Activities

See All

Polling Question

You must log in to answer this question
In which type of patient would you be more likely to use a CDK4/6 inhibitor combination? (Required)
Endocrine-sensitive patient
Endocrine-resistant patient
Either type but depends on the patient
I do not use CDK4/6 inhibitors yet in my patients

Discuss With Your Peers

What is the best sequence for using cyclin-dependent kinase (CDK)4/6 inhibitors?

Related Resources

Downloadable Slide Kit

Clinical Data in HR-Positive Breast Cancer

Download slides with the latest data on CDK4/6 inhibitors in breast cancer.


Clinical Articles

Breast cancer Read article

Cancer treatment reviews Read article

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Read article

Related Links

See All

Steering Committee

Nadia Harbeck, MD, PhD

Steering Committee Chair

Professor, Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany

Javier Cortés, MD, PhD

Head, Breast Cancer and Gynecological Tumours, Ramón y Cajal University Hospital, Oncology Department, Madrid; Clinical Investigator, Breast Cancer Research Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Angelo Di Leo, MD, PhD

Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

Stephen R.D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine, Royal Marsden Hospital, London, United Kingdom

Xavier Pivot, MD, PhD

Professor, J Minjoz University Hospital, Besancon, France

Sunil Verma, MD, MSEd, FRCPC

Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada